
Pubmed-entry ::= {
  pmid 29111983,
  medent {
    em std {
      year 2017,
      month 11,
      day 8,
      hour 6,
      minute 0
    },
    cit {
      title {
        name "Acute Flare of Bullous Pemphigus With Pembrolizumab Used for
 Treatment of Metastatic Urothelial Cancer."
      },
      authors {
        names std {
          {
            name ml "Garje R",
            affil str "Departments of Hematology and Oncology."
          },
          {
            name ml "Chau JJ",
            affil str "Internal Medicine."
          },
          {
            name ml "Chung J",
            affil str "Dermatology, University of Iowa Hospitals and Clinics,
 Iowa City, IA."
          },
          {
            name ml "Wanat K",
            affil str "Dermatology, University of Iowa Hospitals and Clinics,
 Iowa City, IA."
          },
          {
            name ml "Zakharia Y",
            affil str "Departments of Hematology and Oncology."
          }
        }
      },
      from journal {
        title {
          iso-jta "J. Immunother.",
          ml-jta "J Immunother",
          issn "1537-4513",
          name "Journal of immunotherapy (Hagerstown, Md. : 1997)"
        },
        imp {
          date std {
            year 2018,
            month 1
          },
          volume "41",
          issue "1",
          pages "42-44",
          language "eng",
          pubstatus ppublish,
          history {
            {
              pubstatus pubmed,
              date std {
                year 2017,
                month 11,
                day 8,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus medline,
              date std {
                year 2018,
                month 7,
                day 18,
                hour 6,
                minute 0
              }
            },
            {
              pubstatus other,
              date std {
                year 2017,
                month 11,
                day 8,
                hour 6,
                minute 0
              }
            }
          }
        }
      },
      ids {
        pubmed 29111983,
        doi "10.1097/CJI.0000000000000191",
        other {
          db "pmc",
          tag str "PMC6339565"
        },
        other {
          db "mid",
          tag str "NIHMS1005068"
        },
        other {
          db "ELocationID doi",
          tag str "10.1097/CJI.0000000000000191"
        }
      }
    },
    abstract "In the past decade, the resurgence of immunotherapy has changed
 the landscape of cancer therapy. Checkpoint inhibitors targeting cytotoxic
 T-lymphocyte antigen-4, programmed death-1 on lymphocytes, and programmed
 death ligand-1 on tumors cells are currently utilized in the management of
 several cancers. These agents are double-edged sword with the positive effect
 being robust antitumor response but on the other side they can throttle up
 the normal immunologic homeostasis in a negative way, leading to adverse
 autoimmune toxicities. These adverse toxicities are frequent if patients have
 active autoimmune disorders. Here, we report a rare case of quiescent bullous
 pemphigoid which flared after initiation of pembrolizumab, a programmed death
 ligand-1 inhibitor.",
    mesh {
      {
        term "Acute Disease"
      },
      {
        term "Antibodies, Monoclonal, Humanized",
        qual {
          {
            mp TRUE,
            subh "therapeutic use"
          }
        }
      },
      {
        term "Antineoplastic Agents, Immunological",
        qual {
          {
            mp TRUE,
            subh "therapeutic use"
          }
        }
      },
      {
        term "Disease Progression"
      },
      {
        term "Exanthema"
      },
      {
        term "Humans"
      },
      {
        term "Immunotherapy",
        qual {
          {
            mp TRUE,
            subh "methods"
          }
        }
      },
      {
        term "Male"
      },
      {
        term "Middle Aged"
      },
      {
        term "Pemphigus",
        qual {
          {
            subh "diagnosis"
          },
          {
            mp TRUE,
            subh "drug therapy"
          }
        }
      },
      {
        term "Prednisone",
        qual {
          {
            subh "therapeutic use"
          }
        }
      },
      {
        term "Programmed Cell Death 1 Receptor",
        qual {
          {
            subh "immunology"
          }
        }
      },
      {
        term "Skin Diseases, Vesiculobullous",
        qual {
          {
            subh "diagnosis"
          },
          {
            mp TRUE,
            subh "drug therapy"
          }
        }
      },
      {
        term "Urinary Bladder",
        qual {
          {
            mp TRUE,
            subh "pathology"
          }
        }
      },
      {
        term "Urinary Bladder Neoplasms",
        qual {
          {
            subh "diagnosis"
          },
          {
            mp TRUE,
            subh "drug therapy"
          }
        }
      },
      {
        term "Urologic Neoplasms",
        qual {
          {
            subh "diagnosis"
          },
          {
            mp TRUE,
            subh "drug therapy"
          }
        }
      },
      {
        term "Withholding Treatment"
      }
    },
    substance {
      {
        type nameonly,
        name "Antibodies, Monoclonal, Humanized"
      },
      {
        type nameonly,
        name "Antineoplastic Agents, Immunological"
      },
      {
        type nameonly,
        name "Programmed Cell Death 1 Receptor"
      },
      {
        type cas,
        cit "DPT0O3T46P",
        name "pembrolizumab"
      },
      {
        type cas,
        cit "VB0R961HZT",
        name "Prednisone"
      }
    },
    idnum {
      "P30 CA086862/CA/NCI NIH HHS"
    },
    pmid 29111983,
    pub-type {
      "Case Reports",
      "Journal Article"
    },
    status medline
  }
}


